| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Roche Holding AG ADR | Gazyva - (ALLEGORY) | Systemic Lupus Erythematosus | Phase 3 | Data Released | Intravenous | Immunology |
| Roche Holding AG ADR | Gazyva (obinutuzumab) - (INShore) | Idiopathic Nephrotic Syndrome | Phase 3 | Data Released | Intravenous | N/A |
| Roche Holding AG ADR | Giredestrant in combination with everolimus - (evERA) | ER-positive advanced breast cancer | Phase 3 | Data Released | Oral | Oncology |
| Roche Holding AG ADR | Trontinemab - (TRONTIER 1 and 2) | Alzheimer's disease | Phase 3 | Ongoing | Intravenous infusion | Neurology |
| Roche Holding AG ADR | Astegolimab - (ARNASA) | Chronic obstructive pulmonary disease (COPD) | Phase 3 | Data Released | Subcutaneous | Respiratory |
| Roche Holding AG ADR | NXT007 - (NXTAGE) | Hemophilia A | Phase 3 | Trial Planned | Intravenous | Hematology |
| Roche Holding AG ADR | Trontinemab - (Brainshuttle AD) | Alzheimer's Disease | Phase 3 | Trial Planned | Intravenous | Neurology |
| Roche Holding AG ADR | Ocrevus (ocrelizumab) intravenous (IV) infusion | Relapsing multiple sclerosis (RMS) | Phase 3 | Data Released | Intravenous infusion | Neurology |